Loading...
Market
Sarepta Total US Sales from Elevidys by 2025
4
Resolution / Starting Odds
Less than $10 billion • 25%
$10 billion to $20 billion • 25%
$20 billion to $30 billion • 25%
More than $30 billion • 25%
Company financial reports, SEC filings, or reputable financial news sources
Story
Sarepta Therapeutics Set for Major Growth with FDA Approval of Elevidys, $30B Sales Projected
Jun 28, 2024, 11:26 AM
Sarepta Therapeutics ($SRPT) is poised for significant growth following the FDA's approval of its Elevidys treatment for Duchenne Muscular Dystrophy (DMD). The company has received full approval for ambulatory (Amb) patients and accelerated approval for non-ambulatory (Non-Amb) patients. Analysts and investors are optimistic about Sarepta's potential, with BMO Capital projecting $30 billion in total US sales from Elevidys and $1 billion annually from new incidences. BMO Capital has reiterated an Outperform rating with a $200 price target. The approval positions Sarepta as a dominant player in the DMD market with no immediate competition, and revenues are expected to accelerate as more DMD patients seek Elevidys treatment. This growth story is seen as a major milestone for Sarepta.
View original story
Similar markets
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Below $500M • 33%
$500M - $1B • 33%
Above $1B • 34%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Stock price up 0-10% • 33%
Stock price up 10-20% • 33%
Stock price up more than 20% • 34%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Positive • 33%
Neutral • 33%
Negative • 34%
Less than 20% • 33%
20-40% • 33%
More than 40% • 33%